文献速递妇科

CD137+肿瘤浸润淋巴细胞预测卵巢癌生存

CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
PubMed 文献 · Gynecol Oncol · 2024-01-29

研究对47例卵巢癌消化标本行流式细胞术检测,发现CD3+CD137+肿瘤浸润淋巴细胞比例高与总生存改善相关(n=40,r=0.48,P=0.0016),而CD3+或CD3+CD8+肿瘤浸润淋巴细胞差异未影响生存。CD137有潜力成为卵巢癌生存的新型生物标志物。

要点

  • CD3+CD137+肿瘤浸润淋巴细胞比例高与卵巢癌总生存改善相关(n=40,r=0.48,P=0.0016)。
  • CD3+CD137+肿瘤浸润淋巴细胞频率>9.6%者总生存更长(Wilcoxon秩和检验P=0.0032;logrank检验P=0.007)。
  • CD3+或CD3+CD8+肿瘤浸润淋巴细胞差异未影响生存,CD137有潜力成为新型生存生物标志物。

核心结论

  • 卵巢癌消化标本中CD3+CD137+肿瘤浸润淋巴细胞的比例与总生存改善相关,而一般肿瘤浸润淋巴细胞标志物则不然。
  • CD137有潜力成为卵巢癌生存的新型生物标志物。

研究设计与样本

  • 对可存活冻存的卵巢癌消化标本行流式细胞术检测,并进行病历回顾和统计分析。
  • 共纳入47例患者,其中40例诊断为高级别浆液性卵巢癌、乳头状浆液性癌或未分化组织学。

主要发现

  • CD3+CD137+肿瘤浸润淋巴细胞比例高与总生存改善相关(n=40,r=0.48,P=0.0016)。
  • 按中位数将受试者分为CD3+CD137+肿瘤浸润淋巴细胞高组和低组,频率>9.6%者总生存更长(Wilcoxon秩和检验P=0.0032),总生存改善(logrank检验P=0.007)。
  • CD3+或CD3+CD8+肿瘤浸润淋巴细胞的差异未影响生存。
  • 无论胚系突变或减瘤状态如何,CD3+CD137+肿瘤浸润淋巴细胞均可预测总生存。
  • 在晚期高级别浆液性卵巢癌和晚期高级别浆液性卵巢癌初次理想减瘤亚组中,调整年龄和PARP抑制剂使用后,CD3+CD137+肿瘤浸润淋巴细胞与总生存改善相关(分别为P=0.034和P=0.016)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Ovarian cancer (OC) is the leading cause of death from gynecologic malignancy in the United States, and biomarkers of patient outcomes are limited. Data using immunohistochemical (IHC) analysis are mixed regarding whether and which tumor infiltrating lymphocytes (TILs) impact survival, and IHC does not adequately quantify rare cell populations, including CD137+ (4-1BB) tumor-reactive TILs. Our study investigates if a higher percentage of CD3+ CD137+ TILs is associated with improved overall survival (OS) in OC. METHODS: Flow cytometry was performed on viably banked OC digests. Chart review and statistical analysis were performed. Forty-seven patients were included, 40 of whom were diagnosed with high-grade serous ovarian carcinoma (HGSOC), papillary serous carcinoma, or undifferentiated histology. RESULTS: A high percentage of CD3+ CD137+ TILs correlated with improved OS (n = 40, r = 0.48, P = 0.0016). Subjects were divided into CD3+ CD137+ TIL high and low groups by the median. Subjects with high CD3+CD137+ TIL frequencies (>9.6%) had longer OS (Wilcoxon rank-sum test; P = 0.0032) and improved OS (logrank test; P = 0.007). Differences in CD3+ or CD3+ CD8+ TILs did not impact survival. CD3+ CD137+ TILs were predictive of OS regardless of germline mutation or debulking status. Analysis of subgroups including late stage HGSOC and late stage HGSOC with primary optimal cytoreduction indicated CD3+ CD137+ TILs correlated with improved OS after adjusting for age and PARP inhibitor use (P = 0.034 and P = 0.016, respectively). CONCLUSIONS: Prevalence of CD3+ CD137+ TILs in digested OC specimens is associated with improved OS, while general TIL markers are not. CD137 has the potential to be a novel biomarker for survival in OC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Tubridy EA, Eiva MA, Liu F, et al. CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival. Gynecol Oncol. 2024. PMID: 38290413. doi:10.1016/j.ygyno.2024.01.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。